Amiloride inhibits the growth of human colon cancer cells in vitro

J. Y. Koo, D. Parekh, Courtney Townsend, R. Saydjari, B. M. Evers, A. Farre, J. Ishizuka, J. C. Thompson

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Cytoplasmic alkalinization induced by activation of the Na+ H+ antiport plays an essential role in the initiation of cell proliferation. In the present study we examined the effects of amiloride, a specific and reversible inhibitor of Na+ H+ antiporter, on the growth of human colon cancer cells (HT-29). Amiloride (50-800 μm) inhibited the growth of HT-29 cells in a dose-dependent fashion. Forty-three percent inhibition of growth was found at an amiloride concentration of 400 μm after 4 days of treatment. The inhibitory effect of amiloride on growth of HT-29 cells was reversible since removal of amiloride by a media change after 48 h treatment lead to rapid regrowth to control levels. The reversibility of growth inhibition suggests that amiloride is not a non-specific cytotoxin for HT-29 cells. We examined the possible mechanisms for the inhibitory effects of amiloride. Amiloride (400 μM) completely abolished serum-stimulated ODC activity and inhibited difluoromethylornithine (DMFO)-stimulated putrescine uptake by 56%. We conclude that amiloride inhibits the in vitro growth of human colon cancer cells; since ODC-activity and polyamine transport were both inhibited, the inhibitory effects may be mediated in part by polyamine-dependent processes. Amiloride may be a useful agent in the treatment of colon cancer.

Original languageEnglish (US)
Pages (from-to)385-389
Number of pages5
JournalSurgical Oncology
Volume1
Issue number6
DOIs
StatePublished - 1992

Fingerprint

Amiloride
Colonic Neoplasms
Growth
HT29 Cells
Polyamines
In Vitro Techniques
Eflornithine
Sodium-Hydrogen Antiporter
Putrescine
Ion Transport
Cytotoxins
Cell Proliferation

Keywords

  • amiloride
  • antiport
  • colon cancer
  • difluoromethylornithine
  • ornithine decarboxylase
  • putrescine

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

Koo, J. Y., Parekh, D., Townsend, C., Saydjari, R., Evers, B. M., Farre, A., ... Thompson, J. C. (1992). Amiloride inhibits the growth of human colon cancer cells in vitro. Surgical Oncology, 1(6), 385-389. https://doi.org/10.1016/0960-7404(92)90040-R

Amiloride inhibits the growth of human colon cancer cells in vitro. / Koo, J. Y.; Parekh, D.; Townsend, Courtney; Saydjari, R.; Evers, B. M.; Farre, A.; Ishizuka, J.; Thompson, J. C.

In: Surgical Oncology, Vol. 1, No. 6, 1992, p. 385-389.

Research output: Contribution to journalArticle

Koo, JY, Parekh, D, Townsend, C, Saydjari, R, Evers, BM, Farre, A, Ishizuka, J & Thompson, JC 1992, 'Amiloride inhibits the growth of human colon cancer cells in vitro', Surgical Oncology, vol. 1, no. 6, pp. 385-389. https://doi.org/10.1016/0960-7404(92)90040-R
Koo, J. Y. ; Parekh, D. ; Townsend, Courtney ; Saydjari, R. ; Evers, B. M. ; Farre, A. ; Ishizuka, J. ; Thompson, J. C. / Amiloride inhibits the growth of human colon cancer cells in vitro. In: Surgical Oncology. 1992 ; Vol. 1, No. 6. pp. 385-389.
@article{e5e8b5c2d6834aca8a082fd60c237eba,
title = "Amiloride inhibits the growth of human colon cancer cells in vitro",
abstract = "Cytoplasmic alkalinization induced by activation of the Na+ H+ antiport plays an essential role in the initiation of cell proliferation. In the present study we examined the effects of amiloride, a specific and reversible inhibitor of Na+ H+ antiporter, on the growth of human colon cancer cells (HT-29). Amiloride (50-800 μm) inhibited the growth of HT-29 cells in a dose-dependent fashion. Forty-three percent inhibition of growth was found at an amiloride concentration of 400 μm after 4 days of treatment. The inhibitory effect of amiloride on growth of HT-29 cells was reversible since removal of amiloride by a media change after 48 h treatment lead to rapid regrowth to control levels. The reversibility of growth inhibition suggests that amiloride is not a non-specific cytotoxin for HT-29 cells. We examined the possible mechanisms for the inhibitory effects of amiloride. Amiloride (400 μM) completely abolished serum-stimulated ODC activity and inhibited difluoromethylornithine (DMFO)-stimulated putrescine uptake by 56{\%}. We conclude that amiloride inhibits the in vitro growth of human colon cancer cells; since ODC-activity and polyamine transport were both inhibited, the inhibitory effects may be mediated in part by polyamine-dependent processes. Amiloride may be a useful agent in the treatment of colon cancer.",
keywords = "amiloride, antiport, colon cancer, difluoromethylornithine, ornithine decarboxylase, putrescine",
author = "Koo, {J. Y.} and D. Parekh and Courtney Townsend and R. Saydjari and Evers, {B. M.} and A. Farre and J. Ishizuka and Thompson, {J. C.}",
year = "1992",
doi = "10.1016/0960-7404(92)90040-R",
language = "English (US)",
volume = "1",
pages = "385--389",
journal = "Surgical Oncology",
issn = "0960-7404",
publisher = "Elsevier BV",
number = "6",

}

TY - JOUR

T1 - Amiloride inhibits the growth of human colon cancer cells in vitro

AU - Koo, J. Y.

AU - Parekh, D.

AU - Townsend, Courtney

AU - Saydjari, R.

AU - Evers, B. M.

AU - Farre, A.

AU - Ishizuka, J.

AU - Thompson, J. C.

PY - 1992

Y1 - 1992

N2 - Cytoplasmic alkalinization induced by activation of the Na+ H+ antiport plays an essential role in the initiation of cell proliferation. In the present study we examined the effects of amiloride, a specific and reversible inhibitor of Na+ H+ antiporter, on the growth of human colon cancer cells (HT-29). Amiloride (50-800 μm) inhibited the growth of HT-29 cells in a dose-dependent fashion. Forty-three percent inhibition of growth was found at an amiloride concentration of 400 μm after 4 days of treatment. The inhibitory effect of amiloride on growth of HT-29 cells was reversible since removal of amiloride by a media change after 48 h treatment lead to rapid regrowth to control levels. The reversibility of growth inhibition suggests that amiloride is not a non-specific cytotoxin for HT-29 cells. We examined the possible mechanisms for the inhibitory effects of amiloride. Amiloride (400 μM) completely abolished serum-stimulated ODC activity and inhibited difluoromethylornithine (DMFO)-stimulated putrescine uptake by 56%. We conclude that amiloride inhibits the in vitro growth of human colon cancer cells; since ODC-activity and polyamine transport were both inhibited, the inhibitory effects may be mediated in part by polyamine-dependent processes. Amiloride may be a useful agent in the treatment of colon cancer.

AB - Cytoplasmic alkalinization induced by activation of the Na+ H+ antiport plays an essential role in the initiation of cell proliferation. In the present study we examined the effects of amiloride, a specific and reversible inhibitor of Na+ H+ antiporter, on the growth of human colon cancer cells (HT-29). Amiloride (50-800 μm) inhibited the growth of HT-29 cells in a dose-dependent fashion. Forty-three percent inhibition of growth was found at an amiloride concentration of 400 μm after 4 days of treatment. The inhibitory effect of amiloride on growth of HT-29 cells was reversible since removal of amiloride by a media change after 48 h treatment lead to rapid regrowth to control levels. The reversibility of growth inhibition suggests that amiloride is not a non-specific cytotoxin for HT-29 cells. We examined the possible mechanisms for the inhibitory effects of amiloride. Amiloride (400 μM) completely abolished serum-stimulated ODC activity and inhibited difluoromethylornithine (DMFO)-stimulated putrescine uptake by 56%. We conclude that amiloride inhibits the in vitro growth of human colon cancer cells; since ODC-activity and polyamine transport were both inhibited, the inhibitory effects may be mediated in part by polyamine-dependent processes. Amiloride may be a useful agent in the treatment of colon cancer.

KW - amiloride

KW - antiport

KW - colon cancer

KW - difluoromethylornithine

KW - ornithine decarboxylase

KW - putrescine

UR - http://www.scopus.com/inward/record.url?scp=0027104397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027104397&partnerID=8YFLogxK

U2 - 10.1016/0960-7404(92)90040-R

DO - 10.1016/0960-7404(92)90040-R

M3 - Article

VL - 1

SP - 385

EP - 389

JO - Surgical Oncology

JF - Surgical Oncology

SN - 0960-7404

IS - 6

ER -